What is Nostr?
Mike Malaska /
npub1v0m…w4tq
2025-01-05 17:31:42
in reply to nevent1q…l556

Mike Malaska on Nostr: ...the other implication is that you gotta make up for that initial cash outlay on ...

...the other implication is that you gotta make up for that initial cash outlay on the back end.

So assume 16 years of exclusive patent period and average during that period of 50% market penetration you need to have a $1B per year drug to make up for your initial costs.

Big question: Is there a $1B per year driving need RIGHT NOW for a new antibiotic?

(Remember, there are other generic antibiotics, insurance companies will want to try those first.)
Author Public Key
npub1v0m8cmljfy9kze8fucetd2eqv3ptf7v9e092f8r5k2l0wpd485fs4vw4tq